Companies Dominating the Nervous System Active Pharmaceutical Ingredients Landscape
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Company
- Shenzhen Hepalink Pharmaceutical Co. Ltd.
- GSK plc
- F. Hoffmann-La Roche Ltd
- Cipla Inc.
- Eli Lilly and Company
- Novartis AG,
- Teva Pharmaceutical Industries Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of nervous system active pharmaceutical ingredients is assessed at USD 236.63 billion.
The nervous system active pharmaceutical ingredients market size was valued at USD 219.45 billion in 2024 and is expected to reach USD 403.68 billion by 2037, registering around 4.8% CAGR during the forecast period i.e., between 2025-2037. The growing presence of chronic diseases across the globe and the growing geriatric population will boost the market growth.
Asia Pacific industry is predicted to account for largest revenue share of 30% by 2037, led by low labor costs in the region.
The major players in the market are Pfizer, Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Shenzhen Hepalink Pharmaceutical Co. Ltd., GSK plc, F. Hoffmann-La Roche Ltd, Cipla Inc., Eli Lilly and Company, Novartis AG, Teva Pharmaceutical Industries Ltd.
